title: Chryseobacterium indologenes in a woman with acute leukemia in Senegal: a case report.
abstract: BACKGROUND
  This report documents a rare case of Chryseobacterium indologenes urinary tract infection in Senegal. Chryseobacterium indologenes is an uncommon human pathogen reported in hospital outbreaks in Taiwan and there have been some sporadic cases reported in Europe and in the USA mainly from immune-suppressed patients.
  
  
  METHODS
  This case report describes a 42-year-old woman of Wolofa ethnicity who was hospitalized in our Department of Internal Medicine in a Senegalese university teaching hospital, with acute leukemia who died of severe sepsis 10 days following her hospitalization. A strain of Chryseobacterium indologenes isolated from her urine sample was resistant to several beta-lactams including ampicillin (minimum inhibitory concentrations ≥ 256 μg/mL), cefotaxime (minimum inhibitory concentrations 32 μg/mL) and imipenem (minimum inhibitory concentrations ≥ 32 μg/mL), whereas it was susceptible to piperacillin (minimum inhibitory concentrations 16 μg/mL), cefepime (minimum inhibitory concentrations 4 μg/mL), ceftazidime (minimum inhibitory concentrations 4 μg/mL), trimethoprim-sulfamethoxazole (minimum inhibitory concentrations ≤ 0.25 μg/mL) and all tested quinolones including nalidixic acid (minimum inhibitory concentrations ≤ 2 μg/mL).
  
  
  CONCLUSIONS
  Chryseobacterium indologenes although uncommon, is an important pathogen causing infection in hospitalized patients. The management of this infection needs better identification, drug susceptibility testing and monitoring of immunosuppressed patients with long hospitalizations.
authors.affiliation: Laboratoire de Bactériologie-Virologie, Université Cheikh Anta DIOP, CHU Aristide Le Dantec, BP 7325 Dakar, Senegal. oarouna2@gmail.com.
authors.forename: Arouna
authors.initials: A
authors.lastname: Omar
authors.forename: Makhtar
authors.initials: M
authors.lastname: Camara
authors.forename: Seynabou
authors.initials: S
authors.lastname: Fall
authors.forename: Safietou
authors.initials: S
authors.lastname: Ngom-Cisse
authors.forename: Becaye
authors.initials: B
authors.lastname: Fall
authors.forename: Awa
authors.initials: A
authors.lastname: Ba-Diallo
authors.forename: Halimatou
authors.initials: H
authors.lastname: Diop-Ndiaye
authors.forename: Coumba
authors.initials: C
authors.lastname: Toure-Kane
authors.forename: Souleymane
authors.initials: S
authors.lastname: Mboup
authors.forename: Aissatou
authors.initials: A
authors.lastname: Gaye-Diallo
mesh_terms: D000328:Adult; D045247:Chryseobacterium / Q000302:isolation & purification* / Q000502:physiology; D024881:Drug Resistance, Bacterial; D005260:Female; D045826:Flavobacteriaceae Infections / Q000150:complications / Q000382:microbiology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications*; D012675:Senegal; D018805:Sepsis / Q000150:complications / Q000382:microbiology*; D014552:Urinary Tract Infections / Q000150:complications / Q000382:microbiology*